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weighted metric. METHODS: Data were pooled from two 
identical ten-week, multicenter, randomized, double-blind,
placebo-controlled studies of ﬂexible-dose venlafaxine XR
(37.5–300mg/day; mean daily doses in the individual studies
were 132mg and 130mg) and sertraline (50–200mg/day; mean
daily doses in the individual studies were 89mg and 88mg) in
the treatment of DSM-IV MDD (1352 ITT patients). Three
health states were deﬁned using HAM-D17 scores: remission =
HAM-D £ 7; response = HAM-D between eight and 15; no
response = HAM-D > 15. The extended individual model of
Quality-Adjusted Time Without Symptoms and Toxicity (Q-
TWiST) method was applied to develop quality-adjusted remis-
sion days (QUARE), which evaluates treatment trade-offs by
incorporating the duration and patient preference (ie, utility)
associated with each health state. Effectiveness was measured by
the treatment difference on average QUARE days using an
ANOVA model with center as a covariate. Threshold utility
analysis was applied to address the utility uncertainty as a sen-
sitivity analysis. RESULTS: Over the ten-week acute treatment
period, venlafaxine XR was associated with signiﬁcantly more
QUARE days than placebo at all possible utility scenarios (P <
0.05). Sertraline was also associated with signiﬁcantly more
QUARE days than placebo at majority of possible utility sce-
narios. CONCLUSIONS: QUARE is a utility-based measure that
could be used as QALY (Quality Adjusted Life Years) directly in
cost-effectiveness studies. Different deﬁnitions of health states
can be applied to derive QUARE in MDD. Venlafaxine XR and
sertraline were associated with signiﬁcantly more QUARE days
than placebo in ten-week acute treatment of MDD.
PMH41
QUALITY OF LIFE, EMOTIONAL AND PHYSICAL SYMPTOMS
IN DEPRESSION: A LITERATURE REVIEW OF
SYMPTOMATOLOGY AND PATIENT REPORTED OUTCOME
(PRO) INSTRUMENTS
Garcia-Cebrian A1, Staniek V2, Hugonot-Diener L3,Arnould B4,
Monz B5
1Eli Lilly and Company Limited, Surrey, UK; 2Mapi Research Trust,
Lyon, France; 3MedForma, Paris, France; 4Mapi Values, Lyon, France;
5Boehringer Ingelheim GmbH, Ingelheim, Germany
Depression is ranked as having the fourth greatest disease burden
worldwide measured by Disability Adjusted Life Years (DALYs).
Despite the impact of depression on overall morbidity, a signiﬁ-
cant proportion of patients go undiagnosed because the presence
of somatic and painful physical symptoms masks depression.
OBJECTIVES: The aim of this literature review is 1) to assess
existing Patient Reported Outcome (PRO) instruments validated
for use in depression; and 2) to identify to what extent they cover
the whole range of symptoms, especially those somatic and
painful physical symptoms that might hinder recognition of
depression. METHODS: A systematic literature review of pub-
lished studies was conducted using MEDLINE (1951–2004),
EMBASE (1974–2004), and the Mapi Research Trust databases.
Only studies with named, referenced PRO instruments used in
depressed patients were reviewed. The search was restricted to
idiopathic depression. RESULTS: Fifty-nine PRO instruments
were identiﬁed and of those with sufﬁcient data on psychomet-
ric properties, 22 retained for review. Of these, six covered pri-
marily emotional symptoms, three covered somatic symptoms
and 13 both. Excluding the six PRO instruments focused on
emotional symptoms, 16 instruments (eight Quality of Life, two
Activities-of-Daily-Living, four Utility, one Satisfaction and one
Work Productivity) were included in the review. Despite the
variety of PRO instruments covering a wide range of domains,
only a small number presented comprehensive psychometric val-
idation. Indeed, only ﬁve instruments were studied for their
responsiveness to clinical change. CONCLUSION: No single
instrument provides comprehensive coverage of all symptoms of
depression (including emotional, somatic and painful physical
symptoms) and a well documented psychometric validation
status. This literature review suggests the need for additional
work on the responsiveness of instruments in assessing physical
symptoms of depression, as well as further development of
patient satisfaction and work productivity questionnaires.
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OBJECTIVE: Examine the mean difference in hospitalization
and emergency room (ER) visit rates pre and post-initiation on
olanzapine, quetiapine or risperidone. METHODS: Retrospec-
tive analysis of a commercial claims database capturing inpa-
tient, outpatient and prescription drug services. Individuals
having a mental illness diagnosis, and initiated with olanzapine
(N = 8730), quetiapine (N = 5709) or risperidone (N = 9339)
between July 1, 1998 and July 2, 2002 were identiﬁed. Mean
differences in the hospitalization or ER visit rates between the
pre- and post- six month periods across the three-treatments
were examined using ANCOVA, controlling for age, gender,
region, and type of mental illness diagnosis. RESULTS: Individ-
uals initiated with olanzapine or risperidone were found to have
a signiﬁcantly higher difference in the hospitalization (2.19%, p
< 0.0001; 1.72%, p < 0.0001) or ER visit rates (3.80, p < 0.0001;
4.60%, p < 0.0001) post initiation of medication compared to
the six months prior to initiation of medication. In contrast, indi-
viduals who were initiated with quetiapine had a signiﬁcantly
lower difference in the hospitalization (-4.37%, p < 0.0001) or
ER visit rates (-2.89%, p < 0.0001) post-initiation of quetiap-
ine compared to the six months prior-initiation of quetiapine.
CONCLUSION: Quetiapine, unlike olanzapine or risperidone,
may be associated with fewer hospitalizations and ER visits 
after medication initiation. These results may be suggestive of a
more favorable side effect proﬁle and/or better compliance with
Quetiapine, and needs further investigation.
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OBJECTIVE: The severe and persistently mentally (SPMI) have
greater rates of metabolic disorders than the general population
(GP). Wellness programs have demonstrated a reduction in
health care costs for the GP. A program designed to reduce the
rate of metabolic disorders and their risk factors may prove to
signifcantly reduce annual health care cost in the SPMI. The
study goal was to evaluate the effect on metabolic syndrome 
risks of a psychoeducation program designed for SPMI.
METHOD: Overweight patients were randomly selected for 
participation in the study. A psychoeducation program 
which included modules on nutrition and active exercise was
developed and tested. The study had a acute(1hr. 3 X week)
phase for three-months and a maintenance phase (1hr. 1 X
month) for three-months. Vitals and lab tests were taken every
